Phase III, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Examine the Efficacy, Safety, and Pharmacokinetics of Intravenous MLN0002 (300 mg) Infusion in Induction and Maintenance Therapy in Japanese Patients With Moderately or Severely Active Crohn's Disease
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Takeda
- 28 Jul 2017 Planned End Date changed from 1 Apr 2018 to 21 Feb 2019.
- 28 Jul 2017 Planned primary completion date changed from 1 Apr 2018 to 21 Feb 2019.
- 10 Jun 2017 Biomarkers information updated